Development
  • •  Phase III trial for patients at high risk of residual Hodgkin lymphoma following autologous stem cell transplant (ASCT)
       (the AETHERA trial)
  • •  Phase II trial for patients with relapsed or refractory CD30-positive non-Hodgkin lymphomas
    •  Phase II trial for patients with CD30-positive non-lymphoma malignancies
  • •  Phase II trial for retreatment of patients who previously participated in a brentuximab vedotin study
  • •  Phase I trial in combination with chemotherapy for front-line treatment of Hodgkin lymphoma
  • •  Phase I trial in combination with chemotherapy for front-line treatment of CD30-positive mature T-cell malignancies

description
Hodgkin lymphoma is distinguished from other types of lymphoma by the presence of one characteristic type of cell, known as the Reed-Sternberg cell. The Reed-Sternberg cell generally expresses CD30. Systemic ALCL is an aggressive type of
T-cell non-Hodgkin lymphoma (NHL) that also expresses CD30. Brentuximab vedotin (formerly known as SGN-35) is comprised of an anti-CD30 monoclonal antibody linked to a potent cell-killing agent, monomethyl auristatin E (MMAE), using Seattle Genetics’ proprietary technology. The ADC is designed to be stable in the bloodstream, but to release MMAE, an antimicrotubule agent, upon internalization into CD30-expressing tumor cells, resulting in a targeted cell-killing effect.

DEVELOPMENT COLLABORATION
We are jointly developing brentuximab vedotin with Millennium: The Takeda Oncology Company under an agreement where Seattle Genetics has full commercialization rights in the United States and Canada, while Millennium has exclusive rights to commercialize the product candidate in all other countries.

Currently enrolling clinical trials >

Privacy Policy  |  Legal Notice